All Sections

Site Selection

Facility Planning

Workforce Development

Business+Place

AD Editorial Board

Alan Reeves

Senior Managing Director, Global Strategy, Newmark
Alexandra Segers

General Manager, Tochi Advisors
Amy Gerber

Executive Managing Director, Business Incentives Practice, Cushman & Wakefield
Bradley Migdal

Executive Managing Director, Americas Strategic Consulting, Cushman & Wakefield
Brian Corde

Managing Partner, Atlas Insight
Brian Gallagher

Vice President, Corporate Strategy and Development, PPC Partners, Inc.
Chris Chmura, Ph.D.

CEO & Founder, Chmura Economics
Chris Schwinden

Partner, Site Selection Group
Chris Volney

Managing Director, Americas Consulting, CBRE
Courtland Robinson

Director of Business Development, Brasfield & Gorrie
Courtney Dunbar

Site Selection & Economic Development Leader, Burns & McDonnell
David Hickey

Managing Director, Hickey & Associates
Dennis Cuneo

Former Senior Vice President, Toyota Motor North America; Owner , DC Strategic Advisors
Dianne Jones

Managing Director, Business and Economic Incentives, JLL
Eric Stavriotis

Vice Chairman, CBRE
Joe Dunlap

Chief Supply Chain Officer, Legacy Investing
Lauren Berry

Director, Location Analysis and Incentives, Maxis Advisors
Marc Beauchamp

President, SCI Global
Matthew Powers

Site Selection Lead, REDI Site Selection
Scott J. Ziance

Partner and Economic Incentives Practice Leader, Vorys, Sater, Seymour and Pease LLP
Scott Kupperman

Founder, Kupperman Location Solutions
Stephen Gray

President & CEO, Gray Construction

Taiwan-Based PharmaEssentia Plans Puerto Rico, Manufacturing Operations

Area Development News Desk

02/14/2026

Taiwan-based biopharmaceutical company PharmaEssentia Corporation plans to establish operations in Puerto Rico. The $46 million project is expected to create approximately 100 jobs.

The investment will include the construction of a new 40,000-square-foot manufacturing facility that will support growing demand for BESREMi (ropeginterferon alfa-2b), a treatment for hematologic diseases, including cancer. Production is scheduled to begin by 2027.

“Expanding manufacturing capacity outside Taiwan is a core strategic priority for PharmaEssentia as we continue to strengthen supply resilience, scalability, and geographic diversification,” said Ko-Chung Lin, Ph.D., Founder and Chief Executive Officer of PharmaEssentia. “We are proud to take this important step toward establishing U.S.-based manufacturing, with Puerto Rico serving as a future center for the U.S. market. This investment underscores our long-term commitment to reliably serving patients worldwide as demand for BESREMi® continues to grow.”

PharmaEssentia Corporation is a fully integrated global biopharmaceutical company focused on discovering, developing, manufacturing, and commercializing innovative therapeutic biologics for hematologic diseases and cancer. The company’s pipeline emphasizes treatments for rare blood cancer conditions such as myeloproliferative neoplasms, alongside other serious diseases.

“Puerto Rico continues consolidating its position as a hub for advanced manufacturing, with the talent, infrastructure, and regulatory expertise that global companies seek,” noted Economic Development and Commerce (DDEC) Secretary Sebastián Negrón Reichard. “This investment from Asia demonstrates that our island is successfully competing for high-value, long-term projects.”

Project Announcements